Involvement of annexin A8 in the properties of pancreatic cancer

Molecular Carcinogenesis

Volumn 53, Issue 3, 2014, Pages 181-191

  Hata, Harumi ^a   Tatemichi, Masayuki ^a   Nakadate, Toshio ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Annexin A8; Epigenetics; HIF 1alpha; Pancreatic cancer

Indexed keywords

ANNEXIN A8; EPIGENETICS; HIF-1ALPHA; PANCREATIC CANCER;

ANNEXINS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84894275130     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21961     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000; 48:919-922.
3. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: Possible new biochemical target for cancer therapy. Cancer Res 2000; 60:6201-6207.
4. Gerke V, Moss SE. Annexins: From structure to function. Physiol Rev 2002; 82:331-371.
5. Gerke V, Creutz CE, Moss SE. Annexins: Linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005; 6:449-461.
6. Yan X, Yin J, Yao H, Mao N, Yang Y, Pan L. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res 2010; 70:1616-1624.
7. Takano S, Togawa A, Yoshitomi H, et al. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol 2008; 15:3157-3168.
8. Song J, Shih Ie M, Salani R, Chan DW, Zhang Z. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 2007; 13:6842-6849.
9. Song J, Shih Ie M, Chan DW, Zhang Z. Suppression of annexin A11 in ovarian cancer: Implications in chemoresistance. Neoplasia 2009; 11:605-614.
10. Hauptmann R, Maurer-Fogy I, Krystek E, Bodo G, Andree H, Reutelingsperger CP. Vascular anticoagulant beta: A novel human Ca2+/phospholipid binding protein that inhibits coagulation and phospholipase A2 activity. Its molecular cloning, expression and comparison with VAC-alpha. Eur J Biochem 1989; 185:63-71.
11. Reutelingsperger CP, van Heerde W, Hauptmann R, et al. Differential tissue expression of Annexin VIII in human. FEBS Lett 1994; 349:120-124.
12. Stein T, Price KN, Morris JS, et al. Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. Clin Cancer Res 2005; 11:6872-6879.
13. Crotti TN, O'Sullivan RP, Shen Z, et al. Bone matrix regulates osteoclast differentiation and annexin A8 gene expression. Cell Physiol 2011; 226:3413-3421.
14. Grewal T, Enrich C. Annexins-modulators of EGF receptor signalling and trafficking. Cell Signal 2009; 21:847-858.
15. Grewal T, Koese M, Rentero C, Enrich C. Annexin A6-regulator of the EGFR/Ras signalling pathway and cholesterol homeostasis. Int J Biochem Cell Biol 2010; 42:580-584.
16. Goebeler V, Ruhe D, Gerke V, Rescher U. Annexin A8 displays unique phospholipid and F-actin binding properties. FEBS Lett 2006; 580:2430-2434.
17. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418-8423.
18. Gordon GJ, Rockwell GN, Jensen RV, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005; 166:1827-1840.
19. Sarkar A, Yang P, Fan YH, et al. Regulation of the expression of annexin VIII in acute promyelocytic leukemia. Blood 1994; 84:279-286.
20. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63:2649-2657.
21. Gress TM, Wallrapp C, Frohme M, et al. Identification of genes with specific expression in pancreatic cancer by cDNA representational difference analysis. Genes Chromosomes Cancer 1997; 19:97-103.
22. Karanjawala ZE, Illei PB, Ashfaq R, et al. New markers of pancreatic cancer identified through differential gene expression analyses: Claudin 18 and annexin A8. Am J Surg Pathol 2008; 32:188-196.
23. Omura N, Goggins M. Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol 2009; 2:310-326.
24. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007; 1775:138-162.
25. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1:239-259.
26. Tatemichi M, Hata H, Nakadate T. Ectopic expression of activation-induced cytidine deaminase caused by epigenetics modification. Oncol Rep 2011; 25:153-158.
27. Lee MJ, Yu GR, Yoo HJ, et al. ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma. Gastroenterology 2009; 137:1138-1150.
28. Xiong Z, Laird PW. COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25:2532-2534.
29. Tatemichi M, Hata H, Tazawa H, Nakadate T. Lipopolysaccharide induces aberrant hypermethylation of Hic-1 in mouse embryonic fibroblasts lacking p53 gene. Anticancer Res 2008; 28:2101-2108.
30. Laird PW. Cancer epigenetics. Hum Mol Genet 2005; 14:R65-R76.
31. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17:330-339.
32. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60:1835-1839.
33. Hagihara A, Miyamoto K, Furuta J, et al. Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004; 23:8705-8710.
34. Vincent A, Omura N, Hong SM, Jaffe A, Eshleman J, Goggins M. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res 2011; 17:4341-4354.
35. Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003; 63:4158-4166.
36. Tan AC, Jimeno A, Lin SH, et al. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 2009; 3:425-438.
37. Peng DF, Kanai Y, Sawada M, et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 2006; 27:1160-1168.
38. Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000; 7:421-427.
39. Buchler P, Reber HA, Buchler M, et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 2003; 26:56-64.
40. Sun HC, Qiu ZJ, Liu J, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 2007; 30:1359-1367.
41. Akakura N, Kobayashi M, Horiuchi I, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001; 61:6548-6554.
42. Chen C, Yu Z. siRNA targeting HIF-1alpha induces apoptosis of pancreatic cancer cells through NF-kappaB-independent and -dependent pathways under hypoxic conditions. Anticancer Res 2009; 29:1367-1372.
43. Liao SH, Zhao XY, Han YH, et al. Proteomics-based identification of two novel direct targets of hypoxia-inducible factor-1 and their potential roles in migration/invasion of cancer cells. Proteomics 2009; 9:3901-3912.
44. Genetos DC, Wong A, Watari S, Yellowley CE. Hypoxia increases Annexin A2 expression in osteoblastic cells via VEGF and ERK. Bone 2010; 47:1013-1019.
45. Nedjadi T, Kitteringham N, Campbell F, et al. S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer 2009; 101:1145-1154.
46. Sitek B, Sipos B, Alkatout I, et al. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. Proteome Res 2009; 8:1647-1656.
47. Mottet D, Michel G, Renard P, Ninane N, Raes M, Michiels C. Role of ERK and calcium in the hypoxia-induced activation of HIF-1. Cell Physiol 2003; 194:30-44.
48. Bai XF, Ni XG, Zhao P, et al. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol 2004; 10:1466-1470.
49. Zheng L, Foley K, Huang L, et al. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS ONE 2011; 6:e19390.